Revive Therapeutics (FRA:31R) Cyclically Adjusted Book per Share: €0.01 (As of Mar. 2026)


What is Revive Therapeutics Cyclically Adjusted Book per Share?

Revive Therapeutics FRA:31R Cyclically Adjusted Book per Share is €0.01 as of Mar. 2026. The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Revive Therapeutics's adjusted book value per share for the three months ended in Mar. 2026 was €-0.006. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €0.01 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2026-07-11), Revive Therapeutics's current stock price is €0.006. Revive Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was €0.01. Revive Therapeutics's Cyclically Adjusted PB Ratio of today is 0.60.

During the past 12 years, the highest Cyclically Adjusted PB Ratio of Revive Therapeutics was 0.93. The lowest was 0.00. And the median was 0.00.


Revive Therapeutics  (FRA:31R) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Revive Therapeutics's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=0.006/0.01
=0.60

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 12 years, the highest Cyclically Adjusted PB Ratio of Revive Therapeutics was 0.93. The lowest was 0.00. And the median was 0.00.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Revive Therapeutics Cyclically Adjusted Book per Share Related Terms


Revive Therapeutics Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Revive Therapeutics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Revive Therapeutics Cyclically Adjusted Book per Share Chart

Revive Therapeutics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.02 0.00 0.00

Revive Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.01 0.00 0.01

FRA:31R vs ZTS, UTHR: Cyclically Adjusted Book per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Revive Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Revive Therapeutics Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Revive Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Revive Therapeutics's Cyclically Adjusted PB Ratio falls into.



Revive Therapeutics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Revive Therapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.006/132.2623*132.2623
=-0.006

Current CPI (Mar. 2026) = 132.2623.

Revive Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201606 0.012 102.002 0.016
201609 0.023 101.765 0.030
201612 0.021 101.449 0.027
201703 0.026 102.634 0.034
201706 0.020 103.029 0.026
201709 0.015 103.345 0.019
201712 0.015 103.345 0.019
201803 0.013 105.004 0.016
201806 0.009 105.557 0.011
201809 0.006 105.636 0.008
201812 0.003 105.399 0.004
201903 0.013 106.979 0.016
201906 0.009 107.690 0.011
201909 0.006 107.611 0.007
201912 0.005 107.769 0.006
202003 0.024 107.927 0.029
202006 0.024 108.401 0.029
202009 0.025 108.164 0.031
202012 0.024 108.559 0.029
202103 0.066 110.298 0.079
202106 0.062 111.720 0.073
202109 0.051 112.905 0.060
202112 0.046 113.774 0.053
202203 0.034 117.646 0.038
202206 0.029 120.806 0.032
202209 0.026 120.648 0.029
202212 0.020 120.964 0.022
202303 0.023 122.702 0.025
202306 0.021 124.203 0.022
202309 0.020 125.230 0.021
202312 0.018 125.072 0.019
202403 0.016 126.258 0.017
202406 0.012 127.522 0.012
202409 0.011 127.285 0.011
202412 0.010 127.364 0.010
202503 0.009 129.181 0.009
202506 -0.005 129.892 -0.005
202509 -0.005 130.287 -0.005
202512 -0.005 130.366 -0.005
202603 -0.006 132.262 -0.006

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of €0.01 mean?
Revive Therapeutics (FRA:31R) has a Cyclically Adjusted Book per Share of €0.01 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Revive Therapeutics and its competitors.
Is Revive Therapeutics' Cyclically Adjusted Book per Share too high?
Revive Therapeutics' current Cyclically Adjusted Book per Share is €0.01.
How does Revive Therapeutics' Cyclically Adjusted Book per Share compare to ZTS and UTHR?
Revive Therapeutics' Cyclically Adjusted Book per Share of €0.01 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Book per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Revive Therapeutics and its competitors. Revive Therapeutics's current Cyclically Adjusted Book per Share is €0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Revive Therapeutics stock overvalued right now?
Revive Therapeutics (FRA:31R) has a current Cyclically Adjusted Book per Share of €0.01. The current Cyclically Adjusted Book per Share is €0.01. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Revive Therapeutics (FRA:31R), the current Cyclically Adjusted Book per Share is €0.01 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Revive Therapeutics Business Description

Other Exchanges RVVTF:USARVV:Canada
Address 82 Richmond Street East, The Canadian Venture Building, Toronto, ON, CAN, M5C 1P1
Revive Therapeutics Ltd is focused on the research, development, and commercialization of novel psychedelic and cannabinoid-based life sciences products and drug repurposing for infectious diseases. The firm's technology is being developed to fill the medical needs for diseases and disorders such as pain, inflammation, and wound care. The company is exploring the use of Bucillamine for the potential treatment of public health medical emergencies and rare inflammatory disorders. Revive is also advancing the development of Psilocybin-based therapeutics through various programs.